Spruce biosciences reports first quarter 2025 financial results and provides corporate updates

South san francisco, calif.--(business wire)--spruce biosciences, inc. (otc: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended march 31, 2025 and provided corporate updates. “with no fda-approved treatments currently available to treat mps iiib, ta-ert has the potential to be a groundbreaking advancement for patients a.
SPRB Ratings Summary
SPRB Quant Ranking